Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 571-576, November 2005

Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity:☆☆☆☆☆☆

Abstracted from: Pujol JL, Breton JL, Gervais R, et al. Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602–10.

University of Colorado Cancer Center, Denver, CO, USA

published online 19 October 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Eli Lilly, France, Aventis France and Languedoc mutualité Nouvelle Technologie.

☆☆ For correspondence: Dr J-L Pujol, Montpellier academic hospital, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France. Tel/fax: +33 4 67 33 61 36. E-mail: cyber-sante.org.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00138-6

doi:10.1016/j.ctrv.2005.08.001

Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 571-576, November 2005

Article Tools